News

BridgeBio Pharma Highlights ATTRibute-CM Data at 2025 ESC Congress

BridgeBio Pharma Highlights ATTRibute-CM Data at 2025 ESC Congress

Overview of BridgeBio Pharma's Contribution at ESC Congress 2025

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a pioneering biopharmaceutical company dedicated to advancing treatment solutions for genetic diseases, is scheduled to make a significant impact at the upcoming European Society of Cardiology (ESC) Congress 2025. This prestigious event will be noted for showcasing new research developments and innovative therapeutic options, and BridgeBio will take center stage with multiple presentations centered on their groundbreaking ATTRibute-CM study.

Key Presentations During the ESC Congress 2025

Rapid-Fire Oral Presentation

Among the highlights for BridgeBio is a rapid-fire oral presentation that will provide exciting insights into the open-label extension data from the ATTRibute-CM study. This presentation will illustrate several critical findings, including the effects of Acoramidis on cardiovascular mortality rates at the 42-month mark, discussed by leading expert Kevin Alexander, M.D., from Stanford University School of Medicine.

ePosters on Innovative Findings

In addition to the oral presentation, two ePosters will delve into pertinent topics that emerged during the ATTRibute-CM study. Nitasha Sarswat, M.D. from UChicago Medicine, will present findings regarding the impact of Acoramidis on NT-proBNP levels at Month 30. This data aims to better understand how Acoramidis may contribute to improved cardiac health outcomes compared to placebo treatments.

Furthermore, Julian Gillmore, M.D., Ph.D., from University College London, will highlight the results indicating a beneficial effect of Acoramidis on patients with ATTR-CM, measuring changes from baseline in NAC ATTR Stage at Month 30. These well-structured studies offer a comprehensive view of Acoramidis' effectiveness.

Understanding Acoramidis and Its Implications

Acoramidis, marketed as Attruby™, is a transthyretin stabilizer developed for the treatment of cardiac amyloidosis (ATTR-CM). Its clinical goal is to reduce cardiovascular death and related hospitalizations in adults. The promising data surrounding Acoramidis underscores its potential in managing this challenging condition.

Safety Profile of Attruby™

As with any treatment, understanding the safety profile is crucial. Noteworthy adverse reactions associated with Attruby include diarrhea, which occurs at a rate of 11.6% compared to 7.6% in placebo, and upper abdominal pain occurring in 5.5% of patients. Fortunately, most side effects reported in clinical trials were mild and manageable, with discontinuation rates similar to those of placebo group participants.

BridgeBio's Commitment to Genetic Medicine

Founded in 2015, BridgeBio Pharma is on the forefront of biopharmaceutical innovation, striving to deliver transformative medicines for genetic diseases. The company’s mission is rooted in applying cutting-edge science to develop treatments that can significantly improve the lives of patients. The team's extensive expertise in drug discovery and development embodies their commitment to advancing genetic therapies promptly.

Staying Informed about BridgeBio

To stay updated on their latest developments, individuals can visit BridgeBio's official website and follow them across various social media platforms like LinkedIn, Twitter, and Facebook. Keeping abreast of their research achievements can provide deeper insights into how they are shaping the future of medicine.

Contact Information

For media inquiries or to gain further insights into BridgeBio's advancements, you may reach out to their media contact, Bubba Murarka, Executive Vice President, Corporate Development, at contact@bridgebio.com or call (650)-789-8220. Additionally, their investor relations contact, Chinmay Shukla, Senior Vice President, Strategic Finance, can be reached at ir@bridgebio.com.

Frequently Asked Questions

What is the significance of the ATTRibute-CM study?

The study evaluates the efficacy and safety of Acoramidis in treating patients with ATTR-CM, focusing on critical health outcomes such as cardiovascular mortality.

Who will present the data at the ESC Congress?

The data will be presented by notable professionals, including Kevin Alexander, M.D., and Nitasha Sarswat, M.D., among others.

What is Acoramidis, and how does it work?

Acoramidis is a transthyretin stabilizer aimed at treating the cardiomyopathy associated with transthyretin-mediated amyloidosis, helping to stabilize proteins and reduce symptoms.

What adverse reactions are linked to Acoramidis?

Common reactions include diarrhea and upper abdominal pain; however, they typically resolve without treatment discontinuation.

How can I learn more about BridgeBio Pharma?

Visit their official website or follow them on LinkedIn, Twitter, and Facebook for the latest news and updates on their projects and findings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Technical Deep Dive into HONOR X9e Pro's Durability

Updated Category News Views 56

Rethinking Smartphone Power HONOR's latest device, the X9e Pro, flaunts an 11,000mAh battery—stuck it right behind a neat cover without making the thing feel like a brick. You'd think with a battery that big, they’d have to hire bodybuilders to lift it, but nope. At 8.08mm thick and weighing just 203g, this phone bucks the bulk. They’ve squeezed the power of a power...

Continue Reading
Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

Updated Category News Views 111

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Continue Reading
Ryde Group Faces Class Action: Key Investor Takeaways

Updated Category News Views 51

Ryde Group's Tumble: More Than Just Market Volatility When RYDE shares nosedived like a lead balloon, it wasn't due to a market hiccup—it was a darn mess fueled by alleged manipulation. At the heart of this crash are accusations of a blatant pump-and-dump scheme that allegedly swindled investors out of millions. Pump-and-Dump: The Dirty Mechanics This ain't your regular...

Continue Reading
Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Updated Category News Views 96

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

Continue Reading
Clip Expands Horizons with Pulpos Acquisition, New Board Member

Updated Category News Views 109

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Continue Reading
Beta Bionics: Investors on Edge, Legal Moves Underway

Updated Category News Views 37

A Tumultuous Time for Beta Bionics Investors Trouble's brewing for those holding Beta Bionics, Inc. (NASDAQ: BBNX) shares. This isn't just market jitters—it's a full-blown legal tussle. The shareholder-rights law honchos at Johnson Fistel are sounding the alarms, and investors better heed their call before the clock strikes November 3, 2026. There's a class action...

Continue Reading
BAIC FOTON Builds Service Hub in South Africa

Updated Category News Views 28

There's something about seeing a company go all-in on a continent like Africa. This time, it's BAIC FOTON, putting down roots in South Africa with a spanking new training center. On October 27, just before their Africa Partners Conference, they opened up the BAIC FOTON Africa Regional Training Center. This move isn't just about bricks and mortar—it's about creating a...

Continue Reading
Raleigh's Auction Direct Stresses Oil Changes

Updated Category News Views 50

Keeping Engines Humming in Raleigh There's nothing quite like keeping an engine running like clockwork, especially in a place like Raleigh where folks rely on their rides day in and day out. That's where Auction Direct USA steps in, offering professional oil change services aimed at preserving the performance and reliability of used cars. A simple yet crucial service:...

Continue Reading
Elbit Systems Poised for Q3 2026 Earnings Reveal

Updated Category News Views 84

Elbit Systems: A Strategic Player in Defense Here's what's going on with Elbit Systems Ltd. (NASDAQ:ESLT), the Israeli defense heavy hitter. They're gearing up to spill the beans on their Q3 financial results this November 17th. And for those of us keeping an eye on how defense contractors are adapting to today's chaotic geopolitical climate, this is a date you don't want...

Continue Reading
Quarterra Taps Jeb Cox for Texas Development Leadership

Updated Category News Views 70

Big Moves in the Lone Star State Jeb Cox is stepping into some rather big cowboy boots over at Quarterra. With nearly two decades under his belt in the multifamily game, he's saddling up as the new Managing Director of Development in Texas. Quarterra, no stranger to the multifamily rodeo, wants to tighten its grip on the bustling Texas market. And Cox, with his gritty,...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Insurance with AI-Powered Smart Apps by DXC

Updated Category News Views 199

DXC Launches Assure Smart Apps for the Insurance Sector Empowering insurers with smart automation and AI is essential in modernizing operations, enhancing decision-making, and driving growth. DXC Technology (NYSE: DXC), a leading global technology services provider, has introduced the DXC Assure Smart Apps, a comprehensive suite of AI-powered applications designed to...

Continue Reading
AllianceBernstein Fund Updates Portfolio Composition Insight

Updated Category News Views 113

Insight into AllianceBernstein Global High Income Fund AllianceBernstein Global High Income Fund, Inc. (NYSE: AWF) has recently provided a detailed overview of its investment portfolio, highlighting the top fixed-income holdings and overall asset distribution. Understanding these details is key for investors aiming to navigate the complexities of high-yield investments...

Continue Reading
Biden's Administration Takes Passive Stance on Port Labor Negotiations

Updated Category News Views 75

Insights on the Biden Administration's Strategy for Port Negotiations In a noteworthy shift, officials from President Joe Biden's administration are adopting a passive approach in the ongoing labor talks at major East and Gulf Coast ports in the U.S. An unnamed official shared details about this hands-off strategy during recent remarks. The Stalemate in Labor Negotiations...

Continue Reading
Exploring the Expansion of the 3D Cell Culture Market to USD 4 Billion

Updated Category News Views 117

Understanding the Surge in the 3D Cell Culture Market The global market for 3D Cell Culture is witnessing a remarkable growth trajectory, fueled by the increasing emphasis on innovative drug development and effective disease modeling. Current insights reveal that this market, valued at USD 1.4 billion as of 2023, is anticipated to reach an impressive USD 4.0 billion by...

Continue Reading
Walt Farrell Takes Charge as CEO of Atlanta Gas Light and Chattanooga Gas

Updated Category News Views 316

Walt Farrell Appointed as President and CEO at Southern Company Gas Southern Company Gas is excited to announce the appointment of Walt Farrell as the new president and chief executive officer for Atlanta Gas Light and Chattanooga Gas. This transition will take effect at the end of this month, marking a significant development for the company. Future Responsibilities for...

Continue Reading